Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Blood (2006) 108 (11): 3580.

https://doi.org/10.1182/blood.V108.11.3580.3580

Published: 2006

Journal Articles

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

J. Shi, MD, PhD, S. Szmania, BS, N. Rosen, BS, A. Moreno, BS, R. Walker, MD, B. DuPont, MD, K. Hsu, MD, L.A. Baxter-Lowe, PhD, J. Shaughnessy, PhD, B. Barlogie, MD, PhD, M. Cottler-Fox, MD, G. Tricot, MD, PhD, F. van Rhee, MD, PhD

Blood (2005) 106 (11): 3472.

https://doi.org/10.1182/blood.V106.11.3472.3472

Published: 2005

Journal Articles

Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026).

K. A. Hollmig, MD, J. M. Stover, BA, M. C. Fox, MD, L. C. Jackson, BSN, G. Talamo, MD, A. Fassas, MD, M. Zangari, MD, C. K. Lee, MD, F. Van Rhee, MD, PhD, E. Anaissie, MD, G. Tricot, MD, PhD, B. Barlogie, MD, PhD

Blood (2004) 104 (11): 5236.

https://doi.org/10.1182/blood.V104.11.5236.5236

Published: 2004

Journal Articles

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

D.S. Siegel, K.R. Desikan, J. Mehta, S. Singhal, A. Fassas, N. Munshi, E. Anaissie, S. Naucke, D. Ayers, D. Spoon, D. Vesole, G. Tricot, B. Barlogie

Blood (1999) 93 (1): 51–54.

https://doi.org/10.1182/blood.V93.1.51

Published: 1999

Journal Articles

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Blood (1999) 93 (1): 55–65.

https://doi.org/10.1182/blood.V93.1.55

Published: 1999

Journal Articles

Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma

G. Tricot, Y. Gazitt, T. Leemhuis, S. Jagannath, K.R. Desikan, D. Siegel, A. Fassas, S. Tindle, J. Nelson, C. Juttner, A. Tsukamoto, J. Hallagan, K. Atkinson, C. Reading, R. Hoffman, B. Barlogie

Blood (1998) 91 (12): 4489–4495.

https://doi.org/10.1182/blood.V91.12.4489

Published: 1998

Journal Articles

Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation

C.S. Zent, C.S. Wilson, G. Tricot, S. Jagannath, D. Siegel, K.R. Desikan, N. Munshi, D. Bracy, B. Barlogie, A.W. Butch

Blood (1998) 91 (9): 3518–3523.

https://doi.org/10.1182/blood.V91.9.3518

Published: 1998

Journal Articles

Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir

N.C. Munshi, R. Govindarajan, R. Drake, L.M. Ding, R. Iyer, R. Saylors, J. Kornbluth, S. Marcus, Y. Chiang, D. Ennist, L. Kwak, C. Reynolds, G. Tricot, B. Barlogie

Blood (1997) 89 (4): 1334–1340.

https://doi.org/10.1182/blood.V89.4.1334

Published: 1997

Journal Articles

Autotransplants in multiple myeloma: what have we learned?

DH Vesole, G Tricot, S Jagannath, KR Desikan, D Siegel, D Bracy, L Miller, B Cheson, J Crowley, B Barlogie

Blood (1996) 88 (3): 838–847.

https://doi.org/10.1182/blood.V88.3.838.838

Published: 1996

Journal Articles

Graft-versus-myeloma effect: proof of principle

G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi, B Barlogie

Blood (1996) 87 (3): 1196–1198.

https://doi.org/10.1182/blood.V87.3.1196.bloodjournal8731196

Published: 1996

Journal Articles

Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor

Y Gazitt, E Tian, B Barlogie, CL Reading, DH Vesole, S Jagannath, J Schnell, R Hoffman, G Tricot

Blood (1996) 87 (2): 805–811.

https://doi.org/10.1182/blood.V87.2.805.bloodjournal872805

Published: 1996

Journal Articles

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

G Tricot, B Barlogie, S Jagannath, D Bracy, S Mattox, DH Vesole, S Naucke, JR Sawyer

Blood (1995) 86 (11): 4250–4256.

https://doi.org/10.1182/blood.V86.11.4250.bloodjournal86114250

Published: 1995

Journal Articles

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

R Bataille, B Barlogie, ZY Lu, JF Rossi, T Lavabre-Bertrand, T Beck, J Wijdenes, J Brochier, B Klein

Blood (1995) 86 (2): 685–691.

https://doi.org/10.1182/blood.V86.2.685.bloodjournal862685

Published: 1995

Journal Articles

Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells

Y Gazitt, CC Reading, R Hoffman, A Wickrema, DH Vesole, S Jagannath, J Condino, B Lee, B Barlogie, G Tricot

Blood (1995) 86 (1): 381–389.

https://doi.org/10.1182/blood.V86.1.381.bloodjournal861381

Published: 1995

Journal Articles

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

G Tricot, S Jagannath, D Vesole, J Nelson, S Tindle, L Miller, B Cheson, J Crowley, B Barlogie

Blood (1995) 85 (2): 588–596.

https://doi.org/10.1182/blood.V85.2.588.588

Published: 1995

Journal Articles

Interleukin-6 prevents dexamethasone-induced myeloma cell death

J Hardin, S MacLeod, I Grigorieva, R Chang, B Barlogie, H Xiao, J Epstein

Blood (1994) 84 (9): 3063–3070.

https://doi.org/10.1182/blood.V84.9.3063.3063

Published: 1994

Journal Articles

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

DH Vesole, B Barlogie, S Jagannath, B Cheson, G Tricot, R Alexanian, J Crowley

Blood (1994) 84 (3): 950–956.

https://doi.org/10.1182/blood.V84.3.950.950

Published: 1994

Journal Articles

Limited value of myeloablative therapy for late multiple myeloma

R Alexanian, M Dimopoulos, T Smith, K Delasalle, B Barlogie, R Champlin

Blood (1994) 83 (2): 512–516.

https://doi.org/10.1182/blood.V83.2.512.512

Published: 1994

Journal Articles

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

S Jagannath, DH Vesole, L Glenn, J Crowley, B Barlogie

Blood (1992) 80 (7): 1666–1672.

https://doi.org/10.1182/blood.V80.7.1666.1666

Published: 1992

Journal Articles

Primary dexamethasone treatment of multiple myeloma

R Alexanian, MA Dimopoulos, K Delasalle, B Barlogie

Blood (1992) 80 (4): 887–890.

https://doi.org/10.1182/blood.V80.4.887.887

Published: 1992

NARROW

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026).

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma

Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation

Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir

Autotransplants in multiple myeloma: what have we learned?

Graft-versus-myeloma effect: proof of principle

Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

Interleukin-6 prevents dexamethasone-induced myeloma cell death

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

Limited value of myeloablative therapy for late multiple myeloma

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Primary dexamethasone treatment of multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only